Elevated CSF levels of TIMP-1 and TIMP-2 in HD patients, which probably represent a compensatory attempt at controlling unabated MMP activity, could also be potential biomarkers for HD (Lorenzl et al., 2003a; Connolly et al., 2016). This evidence concerns the gene TIMP1 and Huntington disease.